Alicia Jenkins to Fenofibrate
This is a "connection" page, showing publications Alicia Jenkins has written about Fenofibrate.
Connection Strength
2.922
-
Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes. Sci Rep. 2021 09 21; 11(1):18708.
Score: 0.773
-
Fenofibrate, which reduces risk of sight-threatening diabetic retinopathy in type 2 diabetes, is associated with early narrowing of retinal venules: a FIELD trial substudy. Intern Med J. 2022 04; 52(4):676-679.
Score: 0.200
-
Retinopathy risk calculators in the prediction of sight-threatening diabetic retinopathy in type 2 diabetes: A FIELD substudy. Diabetes Res Clin Pract. 2022 Apr; 186:109835.
Score: 0.200
-
The relationship of neutrophil elastase and proteinase 3 with risk factors, and chronic complications in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) sub-study. Diab Vasc Dis Res. 2021 Jul-Aug; 18(4):14791641211032547.
Score: 0.190
-
Relationships of adipocyte-fatty acid binding protein and lipocalin 2 with risk factors and chronic complications in type 2 diabetes and effects of fenofibrate: A fenofibrate Intervention and event lowering in diabetes sub-study. Diabetes Res Clin Pract. 2020 Nov; 169:108450.
Score: 0.180
-
Uric acid predicts long-term cardiovascular risk in type 2 diabetes but does not mediate the benefits of fenofibrate: The FIELD study. Diabetes Obes Metab. 2020 08; 22(8):1388-1396.
Score: 0.175
-
Baseline Circulating FGF21 Concentrations and Increase after Fenofibrate Treatment Predict More Rapid Glycemic Progression in Type 2 Diabetes: Results from the FIELD Study. Clin Chem. 2017 Jul; 63(7):1261-1270.
Score: 0.144
-
Opposite associations between alanine aminotransferase and ?-glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Metabolism. 2016 May; 65(5):783-793.
Score: 0.130
-
Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia. 2015 Sep; 58(9):2035-44.
Score: 0.125
-
The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia. 2015 Mar; 58(3):464-73.
Score: 0.120
-
Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia. 2014 Nov; 57(11):2296-303.
Score: 0.118
-
Peroxisome proliferator-activated receptor a protects capillary pericytes in the retina. Am J Pathol. 2014 Oct; 184(10):2709-20.
Score: 0.118
-
An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes. Diabetes. 2013 Dec; 62(12):3968-75.
Score: 0.113
-
Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2012 Dec; 97(12):4701-8.
Score: 0.105
-
Therapeutic effects of PPARa agonists on diabetic retinopathy in type 1 diabetes models. Diabetes. 2013 Jan; 62(1):261-72.
Score: 0.104
-
Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study. Diabetes Care. 2012 Feb; 35(2):218-25.
Score: 0.098
-
HDL-C and HDL-C/ApoA-I predict long-term progression of glycemia in established type 2 diabetes. Diabetes Care. 2014 Aug; 37(8):2351-8.
Score: 0.029